Study of Generic Pimecrolimus Cream, 1% in the Treatment of Mild to Moderate Atopic Dermatitis
Status:
Completed
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
This is a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study
to Evaluate the Therapeutic Equivalence of a Generic Pimecrolimus Cream, 1% (Glenmark
Pharmaceuticals Ltd) to the Marketed Product ELIDEL® (pimecrolimus) Cream, 1% (Valeant
Pharmaceuticals North America LLC) in the Treatment of Mild to Moderate Atopic Dermatitis
(AD).